ENCOD
  • Donate
  • Covid-19 messages
  • News
  • Organisation
    • About us
    • Our Team
      • WORKING GROUPS
      • STUDIES
      • GENERAL ASSEMBLIES
      • FINANCES
    • Our Mission
    • FAQ
    • IN THE PRESS
    • ANNUAL REPORTS
    • ENCOD MEMBERS
    • INFO FOR MEMBERS
  • Join us
  • Actions & Events
    • CAMPAIGNS
      • FREEDOM TO FARM
        • FREEDOM TO FARM
        • FREEDOM TO FARM IS THE FIRST TEST OF RELIGIOUS FREEDOM
        • FREEDOM TO FARM AND CANNABIS SOCIAL CLUBS FOR PEOPLE WHO USE CANNABIS AS A MEDICINE
        • FREEDOM TO FARM POSTERS
        • FREEDOM TO FARM STICKERS
      • Cannabis Social Clubs
        • HOW TO CREATE A CANNABIS SOCIAL CLUB
        • EXAMPLES OF CSC’S IN EUROPE
        • Cannabis Social Clubs in Aktion
        • PROPOSAL TO REGULATE THE SELF CULTIVATION AND CANNABIS SOCIAL CLUBS IN BELGIUM
        • Catalonia regulates the Cannabis Social Clubs
        • WORKSHOP ‘HOW TO SET UP A CSC IN GERMANY’
      • 2017
      • 2014
      • 2010 – 2013
      • 2009
      • 2008
      • 2007
      • 2006
      • 1995 – 2005
      • EU LOBBY CAMPAIGN
        • 2011
        • 2010
        • 2009
        • 2008
        • 2007
        • 2006
        • 2005
        • 2004
    • ACTION APPEALS
  • Bulletins
  • Video Archive
  • Donate
  • Covid-19 messages
  • News
  • Organisation
    • About us
    • Our Team
      • WORKING GROUPS
      • STUDIES
      • GENERAL ASSEMBLIES
      • FINANCES
    • Our Mission
    • FAQ
    • IN THE PRESS
    • ANNUAL REPORTS
    • ENCOD MEMBERS
    • INFO FOR MEMBERS
  • Join us
  • Actions & Events
    • CAMPAIGNS
      • FREEDOM TO FARM
        • FREEDOM TO FARM
        • FREEDOM TO FARM IS THE FIRST TEST OF RELIGIOUS FREEDOM
        • FREEDOM TO FARM AND CANNABIS SOCIAL CLUBS FOR PEOPLE WHO USE CANNABIS AS A MEDICINE
        • FREEDOM TO FARM POSTERS
        • FREEDOM TO FARM STICKERS
      • Cannabis Social Clubs
        • HOW TO CREATE A CANNABIS SOCIAL CLUB
        • EXAMPLES OF CSC’S IN EUROPE
        • Cannabis Social Clubs in Aktion
        • PROPOSAL TO REGULATE THE SELF CULTIVATION AND CANNABIS SOCIAL CLUBS IN BELGIUM
        • Catalonia regulates the Cannabis Social Clubs
        • WORKSHOP ‘HOW TO SET UP A CSC IN GERMANY’
      • 2017
      • 2014
      • 2010 – 2013
      • 2009
      • 2008
      • 2007
      • 2006
      • 1995 – 2005
      • EU LOBBY CAMPAIGN
        • 2011
        • 2010
        • 2009
        • 2008
        • 2007
        • 2006
        • 2005
        • 2004
    • ACTION APPEALS
  • Bulletins
  • Video Archive
March 23, 2012  |  By Martin Steldinger In 2012

Marijuana-Like Chemicals Inhibit Human Immunodeficiency Virus (HIV) in Late-State AIDS

arton3635

Mount Sinai School of Medicine researchers have discovered that marijuana-like chemicals trigger receptors on human immune cells that can directly inhibit a type of human immunodeficiency virus (HIV) found in late-stage AIDS, according to new findings published online in the journal PLoS ONE.


Medical marijuana is prescribed to treat pain, debilitating weight loss and appetite suppression, side effects that are common in advanced AIDS. This is the first study to reveal how the marijuana receptors found on immune cells—called cannabinoid receptors CB1 and CB2—can influence the spread of the virus. Understanding the effect of these receptors on the virus could help scientists develop new drugs to slow the progression of AIDS.

PLoS ONE – Cannabinoid Receptor 2-Mediated Attenuation of CXCR4-Tropic HIV Infection in Primary CD4+ T Cells

“We knew that cannabinoid drugs like marijuana can have a therapeutic effect in AIDS patients, but did not understand how they influence the spread of the virus itself,” said study author Cristina Costantino, PhD, Postdoctoral Fellow in the Department of Pharmacology and Systems Therapeutics at Mount Sinai School of Medicine. “We wanted to explore cannabinoid receptors as a target for pharmaceutical interventions that treat the symptoms of late-stage AIDS and prevent further progression of the disease without the undesirable side effects of medical marijuana.”

HIV infects active immune cells that carry the viral receptor CD4, which makes these cells unable to fight off the infection. In order to spread, the virus requires that “resting” immune cells be activated. In advanced AIDS, HIV mutates so it can infect these resting cells, gaining entry into the cell by using a signaling receptor called CXCR4. By treating the cells with a cannabinoid agonist that triggers CB2, Dr. Costantino and the Mount Sinai team found that CB2 blocked the signaling process, and suppressed infection in resting immune cells.

Triggering CB1 causes the drug high associated with marijuana, making it undesirable for physicians to prescribe. The researchers wanted to explore therapies that would target CB2 only. The Mount Sinai team infected healthy immune cells with HIV, then treated them with a chemical that triggers CB2 called an agonist. They found that the drug reduced the infection of the remaining cells.
“Developing a drug that triggers only CB2 as an adjunctive treatment to standard antiviral medication may help alleviate the symptoms of late-stage AIDS and prevent the virus from spreading,” said Dr. Costantino. Because HIV does not use CXCR4 to enhance immune cell infection in the early stages of infection, CB2 agonists appear to be an effective antiviral drug only in late-stage disease.
As a result of this discovery, the research team led by Benjamin Chen, MD, PhD, Associate Professor of Infectious Diseases, and Lakshmi Devi, PhD, Professor of Pharmacology and Systems Therapeutics at Mount Sinai School of Medicine, plans to develop a mouse model of late-stage AIDS in order to test the efficacy of a drug that triggers CB2 in vivo. In 2009 Dr. Chen was part of a team that captured on video for the first time the transfer of HIV from infected T-cells to uninfected T-cells.

Funding for this study was provided to Drs. Chen and Devi by the National Institutes of Health in Bethesda, Maryland. Dr. Costantino is supported by a National Institutes of Health Clinical and Translational Science Award grant awarded to Mount Sinai School of Medicine.
About The Mount Sinai Medical Center

The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of the leading medical schools in the United States. The Medical School is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by US News and World Report.
The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation’s oldest, largest and most-respected voluntary hospitals. In 2011, US News and World Report ranked The Mount Sinai Hospital 16th on its elite Honor Roll of the nation’s top hospitals based on reputation, safety, and other patient-care factors. Of the top 20 hospitals in the United States, Mount Sinai is one of 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and US News and World Report and whose hospital is on the US News and World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.

Released: 3/20/2012 1:15 PM EDT
Embargo expired: 3/20/2012 5:00 PM EDT

Source: Mount Sinai Medical Center

Previous StoryTIME FOR A TRUCE IN THE WAR AGAINST DRUGS?
Next StoryMarihuanaähnliche Substanz hemmt HIV im AIDS Spät-Stadium

Related Articles

  • CANCER OF CORRUPTION: THE EU AND THE MONSANTO GMO WHITEWASH
  • arton3954
    GERMAN PATIENTS MAY GROW CANNABIS

Categories

Archives

  • About us
  • Downloads
  • Contact
  • Privacy Policy
  • Legal Notice & Terms of Use
  • Imprint

Copyright ©2018 ThemeFuse. All Rights Reserved

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT

REPUBLISHING TERMS

You may republish this article online or in print under our Creative Commons license. You may not edit or shorten the text, you must attribute the article to ENCOD and you must include the author’s name in your republication.

If you have any questions, please email thujer@gmail.com

License

Creative Commons License AttributionCreative Commons Attribution
Marijuana-Like Chemicals Inhibit Human Immunodeficiency Virus (HIV) in Late-State AIDS